The performance of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the patent expiration in key regions has introduced substantial risk . Investors are now facing the consequences of lower-cost alt